A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT01974440. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in adult participants with previously treated indolent Non-Hodgkin lymphoma.
Study identification
- NCT ID
- NCT01974440
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 403 participants
Conditions and interventions
Conditions
Interventions
- Bendamustine Drug
- Rituximab Drug
- Cyclophosphamide Drug
- Doxorubicin Drug
- Vincristine Drug
- Prednisone Drug
- PCI-32765 (Ibrutinib) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2014 (Actual)
- Primary completion
- May 30, 2022 (Actual)
- Completion
- Jun 21, 2023 (Actual)
- Last update posted
- May 25, 2025
2014 – 2023
United States locations
- U.S. sites
- 32
- U.S. states
- 22
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Gilbert | Arizona | — | — |
| Not listed | Campbell | California | — | — |
| Not listed | Duarte | California | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | Ocala | Florida | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Maywood | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Westwood | Kansas | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Lafayette | Louisiana | — | — |
| Not listed | Scarborough | Maine | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Bethesda | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Ann Arbor | Michigan | — | — |
| Not listed | Battle Creek | Michigan | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Saint Louis Park | Minnesota | — | — |
| Not listed | Denville | New Jersey | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Hickory | North Carolina | — | — |
| Not listed | Pinehurst | North Carolina | — | — |
| Not listed | Bend | Oregon | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Sioux Falls | South Dakota | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Lubbock | Texas | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Green Bay | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 103 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01974440, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 25, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01974440 live on ClinicalTrials.gov.